Justin Chen Li

Justin Chen Li is President & Board Member of Helio Genomics, an AI-based cancer detection company focusing on developing tests that can detect cancer with a simple blood draw. Justin joined Helio as one of the founding team members in 2017 and helped lead the company through two pivotal technology and business acquisitions. Justin has served in a number of key leadership roles at Helio prior to taking on the role of CEO in 2021 and stepping down to President in 2025.

Justin is also Venture Partner at SC Master Fund, a VC platform investing in the Southern California innovation ecosystem. At SC Master Fund, Justin has advised large, publicly traded companies in Southern California on strategic investments and M&A opportunities.

Justin currently serves as an advisor to various early-stage healthcare and biotech companies, primarily in the SF Bay Area and Southern California.

Justin is a CEO Leadership Alliance Orange County member.

Previously, Justin was Consulting Manager for FactSet Research Systems (NASDAQ: FDS). After two years consulting for institutional investors in San Francisco, Justin opened up FactSet’s Los Angeles office.

Previously, Justin worked on the trade floor of Phillips 66 (NASDAQ: PSX), where he held a Market Analyst and Hedge Analyst position, conducting fundamental and statistical analysis on spot and futures markets for diesel and jet fuel. 

Justin started his career at Cellular Biomedicine Group (NASDAQ: CBMG), where he supported valuation models and investor due diligence for its crossover round prior to its public offering on NASDAQ in 2014.

Justin received his BSBA in Finance with honors from the University of Colorado Boulder and MBA in Healthcare with high honors at the Walter A. Haas School of Business at University of California, Berkeley. Justin has been a CFA charterholder since 2017.